Should I buy or sell Iovance Biotherapeutics stock right now?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Iovance Biotherapeutics in the last year. There are currently 10 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" IOVA shares. View IOVA analyst ratings or view top-rated stocks .

What is Iovance Biotherapeutics' stock price target for 2024?

10 analysts have issued 12 month price targets for Iovance Biotherapeutics' stock. Their IOVA share price targets range from $17.00 to $34.00. On average, they expect the company's stock price to reach $24.64 in the next year. This suggests a possible upside of 107.2% from the stock's current price. View analysts price targets for IOVA or view top-rated stocks among Wall Street analysts .

How have IOVA shares performed in 2024?

Iovance Biotherapeutics' stock was trading at $8.13 on January 1st, 2024. Since then, IOVA shares have increased by 46.2% and is now trading at $11.89. View the best growth stocks for 2024 here .

When is Iovance Biotherapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024. View our IOVA earnings forecast .

How were Iovance Biotherapeutics' earnings last quarter?

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) announced its quarterly earnings data on Wednesday, February, 28th. The biotechnology company reported ($0.45) EPS for the quarter, missing the consensus estimate of ($0.44) by $0.01. The biotechnology company had revenue of $0.48 million for the quarter, compared to analysts' expectations of $1.44 million. During the same period in the prior year, the business posted ($0.64) earnings per share.

What ETFs hold Iovance Biotherapeutics' stock?

ETFs with the largest weight of Iovance Biotherapeutics (NASDAQ:IOVA) stock in their portfolio include iShares Genomics Immunology and Healthcare ETF (IDNA) , WisdomTree BioRevolution Fund (WDNA) and Harbor Disruptive Innovation ETF (INNO) . SPDR S&P Biotech ETF (XBI) .

What other stocks do shareholders of Iovance Biotherapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Iovance Biotherapeutics investors own include Applied Materials (AMAT) , Portola Pharmaceuticals (PTLA) , Kadmon (KDMN) , Immunomedics (IMMU) , Bristol-Myers Squibb (BMY) , Seagen (SGEN) , Xtrackers California Municipal Bond ETF (CA) , Advanced Micro Devices (AMD) , BlackRock (BLK) and Novavax (NVAX) .

How do I buy shares of Iovance Biotherapeutics?

Shares of IOVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

Top-Rated StocksTop-Rated

NASDAQ:IOVA

Iovance Biotherapeutics (IOVA) Stock Price, News & Analysis

→ REVEALED: Elon Musk’s Secret A.I. Facility? (From InvestorPlace) (Ad)

Free IOVA Stock Alerts

$11.89

-0.47 (-3.80%)

(As of 04/15/2024 ET)

Compare

Today's Range: $11.66
▼
$12.53
50-Day Range: $8.07
▼
$17.47
52-Week Range: $3.21
▼
$18.33

Volume: 6.39 million shs
Average Volume: 9.01 million shs
Market Capitalization: $3.32 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $24.64

Get Iovance Biotherapeutics alerts:

Iovance Biotherapeutics MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 107.2% Upside
$24.64 Price Target
Short Interest: Bearish
21.08% of Float Sold Short
Dividend Strength: N/A
Sustainability: -0.82
Upright™ Environmental Score
News Sentiment: 1.07
Based on 4 Articles This Week
Insider Trading: Acquiring Shares
$2.29 M Bought Last Quarter
Proj. Earnings Growth: Growing
From ($1.40) to ($0.95) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.73 out of 5 stars

Medical Sector

51st out of 929 stocks

Biological Products, Except Diagnostic Industry

8th out of 148 stocks

4.5

Analyst's Opinion

Consensus Rating
Iovance Biotherapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 10 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Iovance Biotherapeutics has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

2.0

Short Interest

Percentage of Shares Shorted
21.08% of the float of Iovance Biotherapeutics has been sold short.
Short Interest Ratio / Days to Cover
Iovance Biotherapeutics has a short interest ratio ("days to cover") of 4.9.
Change versus previous month
Short interest in Iovance Biotherapeutics has recently decreased by 2.21%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Iovance Biotherapeutics does not currently pay a dividend.
Dividend Growth
Iovance Biotherapeutics does not have a long track record of dividend growth.

4.5

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Iovance Biotherapeutics has received a 70.47% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for physical health" product. See details.
Environmental Sustainability
The Environmental Impact score for Iovance Biotherapeutics is -0.82.

2.3

News and Social Media Coverage

News Sentiment
Iovance Biotherapeutics has a news sentiment score of 1.07. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.66 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 4 news articles for Iovance Biotherapeutics this week, compared to 6 articles on an average week.
Search Interest
Only 93 people have searched for IOVA on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.
MarketBeat Follows
Only 48 people have added Iovance Biotherapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -31% compared to the previous 30 days.

4.2

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Iovance Biotherapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $2,287,500.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
10.40% of the stock of Iovance Biotherapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
77.03% of the stock of Iovance Biotherapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Iovance Biotherapeutics are expected to grow in the coming year, from ($1.40) to ($0.95) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Iovance Biotherapeutics is -6.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Iovance Biotherapeutics is -6.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Iovance Biotherapeutics has a P/B Ratio of 5.21. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad TradeSmith

A.I. Pioneer Issues Urgent Warning to Americans

With artificial intelligence creeping into every facet of our lives, what should you be doing to "A.I.-Proof" your future? It's the question on many of our minds.

Click here to see Louis' new video for yourself.

About Iovance Biotherapeutics Stock (NASDAQ:IOVA)

Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma. It also develops lifileucel in combination with pembrolizumab to treat frontline advanced melanoma patients; LN-145 for the treatment of non-small cell lung cancer (NSCLC) and solid tumor cancers; IOV-4001, which is in Phase 1/2 IOV-GM1-201 clinical trial, for the treatment of NSCLC; and lifileucel for gynecological cancers. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.

IOVA Stock Price History

30 days | 90 days | 365 days | Advanced Chart

IOVA Stock News Headlines

April 9, 2024 | marketbeat.com

The Top 5 Analysts Ranked by Marketbeat and Stocks They Cover

Marketbeat's many investor tools include analysts' rankings and sentiment trackers. These tools help investors and traders gauge market sentiment, showing trends and changes, updated revisions, and new reports.

April 9, 2024 | marketbeat.com

The Top 5 Analysts Ranked by Marketbeat and Stocks They Cover (IOVA)

Analysts rate the stocks, but who rates the analysts? This is a look at five of the highest-rated analysts tracked by Marketbeat.com based on 12-month ROI.

April 16, 2024 | InvestorPlace (Ad)

REVEALED: Elon Musk’s Secret A.I. Facility?

I recently shot this video outside what could be Elon Musk’s biggest secret. What’s happening inside these walls is so important that our government has declared it a matter of national security.

April 9, 2024 | seekingalpha.com

Iovance Biotherapeutics: Riding The Favorable Moment Could Bring Excellent Results

April 5, 2024 | fool.com

Better Growth Biotech Buy: Iovance Biotherapeutics vs CRISPR Therapeutics

April 3, 2024 | bizjournals.com

Obsidian lands $160M Series C —but IPO still in the cards

April 3, 2024 | markets.businessinsider.com

Buy Rating for Werewolf Therapeutics: Innovation and Financial Stability Signal Promising Future in Immunotherapy

April 1, 2024 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Affimed (AFMD) and Atara Biotherapeutics (ATRA)

April 16, 2024 | InvestorPlace (Ad)

REVEALED: Elon Musk’s Secret A.I. Facility?

I recently shot this video outside what could be Elon Musk’s biggest secret. What’s happening inside these walls is so important that our government has declared it a matter of national security.

March 29, 2024 | msn.com

City Council wants the gene therapy industry to hire Philadelphians without a college degree

March 29, 2024 | finance.yahoo.com

Iovance Biotherapeutics (IOVA) Down 6.9% Since Last Earnings Report: Can It Rebound?

March 26, 2024 | fool.com

2 Soaring Growth Stocks That Could Climb Another 47% to 73%, According to Wall Street

March 26, 2024 | seekingalpha.com

Iovance Biotherapeutics: Initial Amtagvi Launch In Focus

March 22, 2024 | globenewswire.com

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

March 19, 2024 | finance.yahoo.com

Iovance Biotherapeutics (NASDAQ:IOVA) shareholders are still up 122% over 1 year despite pulling back 7.1% in the past week

March 18, 2024 | investorplace.com

7 Biotech Stocks Ready to Ride the Sector's Resurgence

March 15, 2024 | markets.businessinsider.com

Analysts Are Bullish on Top Healthcare Stocks: Silk Road Medical (SILK), Arcellx Inc (ACLX)

March 14, 2024 | markets.businessinsider.com

Piper Sandler Maintains Overweight Rating for Iovance Biotherapeutics: Here's What You Need To Know

March 7, 2024 | markets.businessinsider.com

Truist Securities Maintains Buy Rating for Iovance Biotherapeutics: Here's What You Need To Know

March 7, 2024 | fool.com

1 Wall Street Analyst Thinks Iovance Biotherapeutics Stock Is Going to $32. Is It a Buy Around $17?

March 6, 2024 | markets.businessinsider.com

Positive Outlook for Iovance Biotherapeutics: Buy Rating Justified by Clinical Advancements and Strong Financials

March 6, 2024 | fool.com

Iovance Biotherapeutics Stock Has 22% Upside, According to 1 Wall Street Analyst

March 4, 2024 | markets.businessinsider.com

FDA Lifts Clinical Hold On Iovance Biotherapeutics' IOV-LUN-202 Study In Non-Small Cell Lung Cancer

March 4, 2024 | globenewswire.com

Iovance Biotherapeutics Announces FDA has Lifted Clinical Hold on the IOV-LUN-202 Registrational Trial in Non-Small Cell Lung Cancer

March 2, 2024 | fool.com

Could Iovance Biotherapeutics Stock Help You Become a Millionaire?

March 1, 2024 | globenewswire.com

Iovance Biotherapeutics to Present at Upcoming Conferences

March 1, 2024 | markets.businessinsider.com

Iovance Biotherapeutics: Strong Buy on Amtagvi Launch and Positive Growth Prospects

See More Headlines

Receive IOVA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Iovance Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/28/2024
Today: 4/16/2024
Next Earnings (Estimated): 5/14/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Current Symbol: NASDAQ:IOVA
CUSIP: N/A
CIK: 1425205
Web: www.iovance.com
Phone: (650) 260-7120
Fax: N/A
Employees: 557
Year Founded: 2013

Price Target and Rating

Average Stock Price Target: $24.64
High Stock Price Target: $34.00
Low Stock Price Target: $17.00
Potential Upside/Downside: +107.2%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 10 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.88)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-444,040,000.00
Net Margins: N/A
Pretax Margin: -37,638.01%
Return on Equity: -70.93%
Return on Assets: -55.25%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 2.79
Quick Ratio: 2.70

Sales & Book Value

Annual Sales: $1.19 million
Price / Sales: 2,790.75
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.28 per share
Price / Book: 5.21

Miscellaneous

Outstanding Shares: 279,310,000
Free Float: 250,259,000
Market Cap: $3.32 billion
Optionable: Optionable
Beta: 0.62

Social Links

7 Stocks to Buy And Hold Forever

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

Dr. Frederick G. Vogt Esq. (Age 50)
J.D., Ph.D., Interim CEO, President, General Counsel & Corporate Secretary
Comp: $1.39M
Mr. Jean-Marc Bellemin M.B.A. (Age 51)
CFO, Principal Accounting Officer & Treasurer
Comp: $932.2k
Dr. Igor P. Bilinsky (Age 51)
Chief Operating Officer
Comp: $932.2k
Dr. Friedrich Graf Finckenstein M.D. (Age 57)
Chief Medical Officer
Comp: $1.06M
Ms. Sara Pellegrino
Vice President of Investor Relations & Public Relations
Ms. Tracy Winton
Senior Vice President of Human Resources
Mr. Howard B. Johnson M.B.A. (Age 64)
Chief Business Officer
Mr. James Ziegler M.B.A.
Executive Vice President of Commercial
Dr. Raj K. Puri M.D.
Ph.D., Executive VP of Regulatory Strategy & Translational Medicine
Mr. Brian Shew M.B.A.
Senior VP & Head of Digital and Information Technology

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

IOVA Stock Analysis - Frequently Asked Questions

Should I buy or sell Iovance Biotherapeutics stock right now?: 10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Iovance Biotherapeutics in the last year. There are currently 10 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" IOVA shares.
View IOVA analyst ratings or view top-rated stocks.
What is Iovance Biotherapeutics' stock price target for 2024?: 10 analysts have issued 12 month price targets for Iovance Biotherapeutics' stock. Their IOVA share price targets range from $17.00 to $34.00. On average, they expect the company's stock price to reach $24.64 in the next year. This suggests a possible upside of 107.2% from the stock's current price.
View analysts price targets for IOVA or view top-rated stocks among Wall Street analysts.
How have IOVA shares performed in 2024?: Iovance Biotherapeutics' stock was trading at $8.13 on January 1st, 2024. Since then, IOVA shares have increased by 46.2% and is now trading at $11.89.
View the best growth stocks for 2024 here.
When is Iovance Biotherapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our IOVA earnings forecast.

How were Iovance Biotherapeutics' earnings last quarter?: Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) announced its quarterly earnings data on Wednesday, February, 28th. The biotechnology company reported ($0.45) EPS for the quarter, missing the consensus estimate of ($0.44) by $0.01. The biotechnology company had revenue of $0.48 million for the quarter, compared to analysts' expectations of $1.44 million. During the same period in the prior year, the business posted ($0.64) earnings per share.
What ETFs hold Iovance Biotherapeutics' stock?: ETFs with the largest weight of Iovance Biotherapeutics (NASDAQ:IOVA) stock in their portfolio include iShares Genomics Immunology and Healthcare ETF (IDNA), WisdomTree BioRevolution Fund (WDNA) and Harbor Disruptive Innovation ETF (INNO).SPDR S&P Biotech ETF (XBI).
What other stocks do shareholders of Iovance Biotherapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Iovance Biotherapeutics investors own include Applied Materials (AMAT), Portola Pharmaceuticals (PTLA), Kadmon (KDMN), Immunomedics (IMMU), Bristol-Myers Squibb (BMY), Seagen (SGEN), Xtrackers California Municipal Bond ETF (CA), Advanced Micro Devices (AMD), BlackRock (BLK) and Novavax (NVAX).
How do I buy shares of Iovance Biotherapeutics?: Shares of IOVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:IOVA) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial